Under the terms of the agreement, Yabao will exclusively own rights to commercialize certain Salus Pharma-developed products outside the U.S. and to manufacture for worldwide markets, while Salus Pharma will retain rights to commercialize in the U.S. Financial terms were not disclosed.
Yabao Pharmaceutical president of R&D and head of international business Peng Wang said: "Yabao is excited to collaborate with Salus Pharma, a specialty pharmaceutical company engaged in the research and development of high technological barrier controlled release formulation. This transaction represents our first generic drug partnership with Salus within this year.
"This partnership further demonstrates that Yabao’s competitive R&D and manufacturing have expanded into developed markets."